首页> 外文期刊>Veterinary Radiology & Ultrasound >Definitive-intent intensity modulated radiotherapy for modified-Adams' stage 4 canine sinonasal cancer: A retrospective study of 29 cases (2011-2017)
【24h】

Definitive-intent intensity modulated radiotherapy for modified-Adams' stage 4 canine sinonasal cancer: A retrospective study of 29 cases (2011-2017)

机译:明确的强度调节放疗修饰ADAMS阶段4犬Sinonasal癌症:回顾性研究29例(2011-2017)

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Dogs with sinonasal tumors with cribriform plate lysis (modified Adams' stage 4) treated with non-conformal definitive radiotherapy (RT) have short median survivals of 6-7 months. Intensity-modulated radiotherapy with its greater conformality and tumor dose homogeneity may result in more favorable outcomes. Dogs with epithelial or mesenchymal sinonasal tumors and CT evidence of cribriform lysis that received 10 daily fractions of 4.2 Gray using IMRT by helical tomotherapy were included in this single-institution retrospective case series study. Dogs with distant metastasis, previous treatment, or concurrent chemotherapy were excluded. Based on CT, tumors were divided into two groups: cribriform plate lysis only (stage 4a) or intracranial extension (stage 4b). Twenty-nine dogs were included, 23 with carcinoma and six with sarcoma. Eight dogs had stage 4b tumors; two presented with neurologic signs. Two dogs had lymph node metastasis at diagnosis, one confirmed and one suspected. Radiation dose distributions were standardized and patient positioning for RT was verified daily using on-board megavoltage CT. All evaluable dogs had improvement of clinical signs. Median progression free survival was 177 days (95% CI, 128-294 days). Median overall survival was 319 days (95% CI, 188-499 days). Radiotherapy was well tolerated. The most common side effect was grade 1 or 2 oral mucositis. Two dogs that received additional treatment at progression (stereotactic RT [1]; surgery [1]) developed significant late effects. Image-guided definitive-intent IMRT may improve survival in dogs with modified Adams' stage 4 sinonasal tumors and is associated with low morbidity. Intracranial tumor extension was not prognostic in this cohort of uniformly treated dogs.
机译:经非适形放疗(RT)治疗的犬鼻窦肿瘤筛板松解术(改良Adams's 4期)的中位生存期短,为6-7个月。调强放疗具有更好的适形性和肿瘤剂量均匀性,可能会带来更有利的结果。这项单机构回顾性病例系列研究纳入了患有鼻腔上皮性或间叶性肿瘤的狗,以及CT证据显示筛状溶解的狗,这些狗每天接受10次4.2灰色调强放射治疗。排除有远处转移、既往治疗或同时化疗的狗。根据CT,肿瘤被分为两组:仅筛板松解术(4a期)或颅内扩张术(4b期)。包括29只狗,23只患有癌症,6只患有肉瘤。8只狗患有4b期肿瘤;两人出现神经症状。两只狗在诊断时有淋巴结转移,一只确诊,一只疑似。辐射剂量分布标准化,每天使用车载兆伏CT验证患者的RT定位。所有可评估犬的临床症状均有改善。中位无进展生存期为177天(95%CI,128-294天)。中位总生存期为319天(95%可信区间188-499天)。放疗耐受性良好。最常见的副作用是1级或2级口腔粘膜炎。在进展期接受额外治疗(立体定向RT[1];手术[1])的两只狗出现了显著的迟发效应。图像引导下的最终目的性调强放射治疗可提高改良Adams'4期鼻窦肿瘤犬的生存率,且发病率较低。在这组接受统一治疗的狗中,颅内肿瘤扩展不是预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号